Literature DB >> 22088989

Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.

Sai-Hong Ignatius Ou1, Michele Azada, Joni Dy, Jonathan A Stiber.   

Abstract

Crizotinib, a dual MET/ALK inhibitor, is now in advanced clinical development for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). We have observed several patients who developed profound but asymptomatic sinus bradycardia (HR ≤45) during the course of crizotinib treatment. Herein, we describe the clinical characteristics of three separate patients enrolled in the A8081001 trial (NCT00585195) who developed asymptomatic profound sinus bradycardia with their accompanying electrocardiogram tracings.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22088989     DOI： 10.1097/JTO.0b013e3182307e06

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


  16 in total

Review 1.  Treating ALK-positive lung cancer--early successes and future challenges.

Authors:  D Ross Camidge; Robert C Doebele
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

Review 2.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

3.  Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.

Authors:  Evelyn M Brosnan; Andrew J Weickhardt; Xian Lu; Delee A Maxon; Anna E Barón; Michel Chonchol; D Ross Camidge
Journal:  Cancer       Date:  2013-11-20       Impact factor: 6.860

Review 4.  Cancer chemotherapy and cardiac arrhythmias: a review.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

Review 5.  Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2022-01-13       Impact factor: 5.606

Review 6.  Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jin-Yuan Shih; James Chih-Hsin Yang
Journal:  Ther Adv Med Oncol       Date:  2015-09       Impact factor: 8.168

Review 7.  Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.

Authors:  Sai-Hong Ignatius Ou
Journal:  Drug Des Devel Ther       Date:  2011-11-23       Impact factor: 4.162

Review 8.  Crizotinib: A comprehensive review.

Authors:  Arvind Sahu; Kumar Prabhash; Vanita Noronha; Amit Joshi; Saral Desai
Journal:  South Asian J Cancer       Date:  2013-04

9.  Systemic cancer therapy: achievements and challenges that lie ahead.

Authors:  Michael O Palumbo; Petr Kavan; Wilson H Miller; Lawrence Panasci; Sarit Assouline; Nathalie Johnson; Victor Cohen; Francois Patenaude; Michael Pollak; R Thomas Jagoe; Gerald Batist
Journal:  Front Pharmacol       Date:  2013-05-07       Impact factor: 5.810

10.  Clinical use of crizotinib for the treatment of non-small cell lung cancer.

Authors:  Patrick J Roberts
Journal:  Biologics       Date:  2013-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.